The results consistently demonstrated that PCa patients with GATA2 copy gain indicates significantly increased frequency of biochemical relapse, metastasis and shorter disease-specific survival in two different PCa cohorts (Fig. 1o-q). The gene discussed is GATA2; the disease is posterior cortical atrophy.